[The influence of histamine and second generation of antihistamine drugs on cardiovascular system]

[Article in Polish]

Affiliations

Review

[Article in Polish]

Teresa Adamek-Guzik et al. Pol Arch Med Wewn. 2002 Aug.

. 2002 Aug;108(2):785-95.

¹ Katedra i Klinika Chorób Wewnetrznych i Medycyny Wsi Collegium Medicum UJ w Krakowie.

No abstract available

Similar articles

Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects.
Kreutner W, Hey JA, Chiu P, Barnett A. Kreutner W, et al. Arzneimittelforschung. 2000 May;50(5):441-8. doi: 10.1055/s-0031-1300228. Arzneimittelforschung. 2000. PMID: 10858871
Antihistamine meta-analysis leaves uncertainty.
Shapiro GG. Shapiro GG. J Allergy Clin Immunol. 2003 Apr;111(4):695-6. doi: 10.1067/mai.2003.1410. J Allergy Clin Immunol. 2003. PMID: 12704345 No abstract available.
Desloratadine inhibits human skin mast cell activation and histamine release.
Weller K, Maurer M. Weller K, et al. J Invest Dermatol. 2009 Nov;129(11):2723-6. doi: 10.1038/jid.2009.134. Epub 2009 Jun 11. J Invest Dermatol. 2009. PMID: 19516262 No abstract available.
Comparative pharmacology of the H1 antihistamines.
del Cuvillo A, Mullol J, Bartra J, Dávila I, Jáuregui I, Montoro J, Sastre J, Valero AL. del Cuvillo A, et al. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3-12. J Investig Allergol Clin Immunol. 2006. PMID: 17357372 Review. No abstract available.
The pharmacology and mechanisms of action of histamine H1-antagonists.
Rimmer SJ, Church MK. Rimmer SJ, et al. Clin Exp Allergy. 1990 Aug;20 Suppl 2:3-17. doi: 10.1111/j.1365-2222.1990.tb02456.x. Clin Exp Allergy. 1990. PMID: 1699644 Review. No abstract available.